D. Gully

发表

Identification of Two Amino Acids of the Human Cholecystokinin-A Receptor That Interact with the N-terminal Moiety of Cholecystokinin*

B. Maigret, N. Vaysse, L. Moroder, 1997, The Journal of Biological Chemistry.

Arginine 197 of the cholecystokinin‐A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin

B. Maigret, N. Vaysse, S. Silvente-Poirot, 2008, Protein science : a publication of the Protein Society.

Arginine 336 and Asparagine 333 of the Human Cholecystokinin-A Receptor Binding Site Interact with the Penultimate Aspartic Acid and the C-terminal Amide of Cholecystokinin*

B. Maigret, N. Vaysse, Jean Martinez, 1999, The Journal of Biological Chemistry.

Neurotensinergic Systems

M. Meaney, A. Sarrieau, C. Betancur, 2005 .

X-ray structural characterization of SR 142948, a novel potent synthetic neurotensin receptor antagonist.

R. Boigegrain, F. Durant, L. Quéré, 1998, Bioorganic & medicinal chemistry letters.

SR142948A is a potent antagonist of the cardiovascular effects of neurotensin.

J. Herbert, P. Schaeffer, A. Bernat, 1998, Journal of cardiovascular pharmacology.

Neurotensin induces the release of prostacyclin from human umbilical vein endothelial cells in vitro and increases plasma prostacyclin levels in the rat.

J. Herbert, P. Schaeffer, A. Bernat, 1997, European journal of pharmacology.

Peripheral neurotensin participates in the modulation of pre- and postprandial intestinal motility in rats

S. Pellissier, M. Roche, D. Gully, 1996, Neuropeptides.

The 100-kDa Neurotensin Receptor Is gp95/Sortilin, A Non-G-Protein-coupled Receptor*

M. Kaghad, P. Ferrara, D. Caput, 1998, The Journal of Biological Chemistry.

Stable Expression of the Cloned Rat Brain Neurotensin Receptor into Fibroblasts: Binding Properties, Photoaffinity Labeling, Transduction Mechanisms, and Internalization

P. Kitabgi, J. Vincent, J. Chabry, 1994, Journal of neurochemistry.

Use of Nonpeptide Antagonists to Explore the Physiological Roles of Neurotensin

W. Rostène, H. Boudin, C. Betancur, 1997, Annals of the New York Academy of Sciences.

Human Umbilical Vein Endothelial Cells Express High Affinity Neurotensin Receptors Coupled to Intracellular Calcium Release (*)

J. Herbert, P. Savi, P. Schaeffer, 1995, The Journal of Biological Chemistry.

Inhibition of neurotensin‐induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692

B. Evers, C. Townsend, D. Gully, 1997, Cancer.

Met-195 of the Cholecystokinin-A Receptor Interacts with the Sulfated Tyrosine of Cholecystokinin and Is Crucial for Receptor Transition to High Affinity State*

B. Maigret, N. Vaysse, S. Silvente-Poirot, 1998, The Journal of Biological Chemistry.

Negative modulation of nitric oxide production by neurotensin as a putative mechanism of the diuretic action of SR 48692 in rats

J. Maffrand, G. Le Fur, T. Croci, 1997, British journal of pharmacology.

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

G. Griebel, J. Simiand, P. Soubrié, 2002, The Journal of pharmacology and experimental therapeutics.

CCK‐JMV‐180 acts as an antagonist of the CCKA receptor in the human IMR‐32 neuroblastoma cell line

J. Herbert, P. Schaeffer, V. Prabonnaud, 1994, FEBS letters.

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related

G. Griebel, J. Simiand, P. Soubrié, 2002, The Journal of pharmacology and experimental therapeutics.

3-thiazol-2-amine Hydrochloride ( SSR 125543 A ) , a Potent and Selective Corticotrophin-Releasing Factor 1 Receptor Antagonist . II . Characterization in Rodent Models of Stress-Related Disorders

G. Griebel, J. Simiand, P. Soubrié, 2002 .

Neurotensin and a non‐peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice

M. Laburthe, J. Maoret, C. Rouyer‐Fessard, 1999, International journal of cancer.

Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth.

H. J. Kim, B. Evers, C. Townsend, 1996, Surgical oncology.

Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor.

P. Soubrié, D. Gully, M. Canton, 1993, Proceedings of the National Academy of Sciences of the United States of America.

In vitro functional evidence of different neurotensin‐receptors modulating the motor response of human colonic muscle strips

P. Chalon, P. Ferrara, J. Maffrand, 1999, British journal of pharmacology.